U.S. flag

An official website of the United States government

  1. Home
  2. About NIDDK
  3. Staff Directory
  4. Meryl A. Waldman, M.D.
Go to Staff Directory home

Meryl A. Waldman, M.D.

Meryl Waldman.
Scientific Focus Areas: Immunology, Clinical Research

Professional Experience

  • Senior Research Physician NIDDK, NIH, 2020-present
  • Chief, Clinical Nephrology Consult Service, 2020-present
  • Director, Dialysis, 2020-present
  • Nancy Nossal Mentorship Award, 2022
  • NIAMS Director’s Group Award :COVID-19 Systemic Autoimmunity 2022
  • NIDDK Clinical Director's Award, 2020
  • Associate Research Physician, NIDDK, NIH, 2018-2020
  • Staff Clinician, NIDDK, NIH, 2006-present
  • Clinical Instructor, Columbia University, New York Presbyterian Hospital, Glomerular Disease Institute, 2005-2006
  • Nephrology Fellowship, Hospital of the University of Pennsylvania, 2001-2005
  • Internal medicine-Pediatrics Combined Residency, Baystate Medical Center, 1997-2001
  • M.D., Tufts University School of Medicine, 1997

Current Research

The focus of my research is the natural history, pathogenesis, and treatment of immunologically mediated glomerular diseases particularly  membranous nephropathy. The goal of my research is to find novel ways to suppress autoimmune responses that lead to kidney disease as well as to find more sensitive methods to monitor disease activity.

Select Publications

Predictors and significance of kidney dysfunction in patients with chronic graft-versus-host disease.
Beshensky D, Pirsl F, Holtzman NG, Steinberg SM, Mays JW, Cowen EW, Comis LE, Joe GO, Magone MT, Schulz E, Waldman MA, Pavletic SZ.
Bone Marrow Transplant (2023 Oct) 58:1112-1120. Abstract/Full Text
Prediagnostic Appearance of Thrombospondin Type-1 Domain 7A Autoantibodies in Membranous Nephropathy.
Burbelo PD, Olson SW, Keller JM, Joshi M, Schwartz DM, Chuang YJ, Lambeau G, Beck LH Jr, Waldman M.
Kidney360 (2023 Feb 1) 4:217-225. Abstract/Full Text
View More Publications

Research in Plain Language

I study new combinations of agents that reduce the activity of the immune system to treat individuals with immune-mediated kidney disease in which  kidney cells are damaged by immune responses or inflammation.

Last Reviewed October 2023